---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000436"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:10:59.453532+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Therapeutics outlines 2023 milestones; MRT-2359 Fast Track designation from FDA

## Summary
- MRT-2359 granted FDA Fast Track for previously treated metastatic NSCLC with L-MYC or N-MYC expression.
- Initial Phase 1 data from ongoing Phase 1/2 trial of MRT-2359 expected in H2 2023.
- Company anticipates nomination of multiple development candidates in 2023 across oncology, autoimmune, and inflammatory indications.
- Presentation at J.P. Morgan Healthcare Conference on Jan 11, 2023.

## SEC filing metadata
- accession: 0000950170-23-000436
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017023000436/0000950170-23-000436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017023000436/glue-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000436
- JSON: https://secwatch.observer/filing/0000950170-23-000436.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000436.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.